These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 25952672)

  • 21. Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy.
    Jounaidi Y; Waxman DJ
    Cancer Res; 2001 Jun; 61(11):4437-44. PubMed ID: 11389073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment.
    Ma J; Waxman DJ
    Mol Cancer Ther; 2007 Nov; 6(11):2879-90. PubMed ID: 17989319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts.
    Geoerger B; Gaspar N; Opolon P; Morizet J; Devanz P; Lecluse Y; Valent A; Lacroix L; Grill J; Vassal G
    Int J Cancer; 2008 Jul; 123(1):209-16. PubMed ID: 18386816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity.
    Verschuere T; Toelen J; Maes W; Poirier F; Boon L; Tousseyn T; Mathivet T; Gerhardt H; Mathieu V; Kiss R; Lefranc F; Van Gool SW; De Vleeschouwer S
    Int J Cancer; 2014 Feb; 134(4):873-84. PubMed ID: 23929302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improvement of antitumor effect of intratumoral injection of immature dendritic cells into irradiated tumor by cyclophosphamide in mouse colon cancer model.
    Son CH; Shin DY; Kim SD; Park HS; Jung MH; Bae JH; Kang CD; Yang K; Park YS
    J Immunother; 2012 Oct; 35(8):607-14. PubMed ID: 22996366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
    Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS
    Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased tumor oxygenation and drug uptake during anti-angiogenic weekly low dose cyclophosphamide enhances the anti-tumor effect of weekly tirapazamine.
    Doloff JC; Khan N; Ma J; Demidenko E; Swartz HM; Jounaidi Y
    Curr Cancer Drug Targets; 2009 Sep; 9(6):777-88. PubMed ID: 19754361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leukocyte Differentiation by Histidine-Rich Glycoprotein/Stanniocalcin-2 Complex Regulates Murine Glioma Growth through Modulation of Antitumor Immunity.
    Roche FP; Pietilä I; Kaito H; Sjöström EO; Sobotzki N; Noguer O; Skare TP; Essand M; Wollscheid B; Welsh M; Claesson-Welsh L
    Mol Cancer Ther; 2018 Sep; 17(9):1961-1972. PubMed ID: 29945872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor pO₂ as a surrogate marker to identify therapeutic window during metronomic chemotherapy of 9L gliomas.
    Mupparaju S; Hou H; Lariviere JP; Swartz HM; Khan N
    Adv Exp Med Biol; 2011; 701():107-13. PubMed ID: 21445776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors.
    El Andaloussi A; Sonabend AM; Han Y; Lesniak MS
    Glia; 2006 Nov; 54(6):526-35. PubMed ID: 16906541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic antitumor activity of metronomic dosing of cyclophosphamide in combination with doxorubicin-containing PEGylated liposomes in a murine solid tumor model.
    Ishida T; Shiraga E; Kiwada H
    J Control Release; 2009 Mar; 134(3):194-200. PubMed ID: 19095022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response.
    Weir GM; Hrytsenko O; Stanford MM; Berinstein NL; Karkada M; Liwski RS; Mansour M
    Oncoimmunology; 2014; 3(8):e953407. PubMed ID: 25960932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early gene expression analysis in 9L orthotopic tumor-bearing rats identifies immune modulation in molecular response to synchrotron microbeam radiation therapy.
    Bouchet A; Sakakini N; El Atifi M; Le Clec'h C; Brauer E; Moisan A; Deman P; Rihet P; Le Duc G; Pelletier L
    PLoS One; 2013; 8(12):e81874. PubMed ID: 24391709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas.
    Kim JT; Kim JS; Ko KW; Kong DS; Kang CM; Kim MH; Son MJ; Song HS; Shin HJ; Lee DS; Eoh W; Nam DH
    Oncol Rep; 2006 Jul; 16(1):33-9. PubMed ID: 16786120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms and pathways of innate immune activation and regulation in health and cancer.
    Cui J; Chen Y; Wang HY; Wang RF
    Hum Vaccin Immunother; 2014; 10(11):3270-85. PubMed ID: 25625930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the bHLH transcriptional networks by mutated E proteins in experimental glioma.
    Beyeler S; Joly S; Fries M; Obermair FJ; Burn F; Mehmood R; Tabatabai G; Raineteau O
    Stem Cells; 2014 Oct; 32(10):2583-95. PubMed ID: 24965159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene.
    Wei MX; Tamiya T; Chase M; Boviatsis EJ; Chang TK; Kowall NW; Hochberg FH; Waxman DJ; Breakefield XO; Chiocca EA
    Hum Gene Ther; 1994 Aug; 5(8):969-78. PubMed ID: 7948146
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis.
    Jia L; Waxman DJ
    Cancer Lett; 2013 Apr; 330(2):241-9. PubMed ID: 23228633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Forced downregulation of RACK1 inhibits glioma development by suppressing Src/Akt signaling activity.
    Peng R; Jiang B; Ma J; Ma Z; Wan X; Liu H; Chen Z; Cheng Q; Chen R
    Oncol Rep; 2013 Nov; 30(5):2195-202. PubMed ID: 24008630
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
    Kessler T; Sahm F; Blaes J; Osswald M; Rübmann P; Milford D; Urban S; Jestaedt L; Heiland S; Bendszus M; Hertenstein A; Pfenning PN; Ruiz de Almodóvar C; Wick A; Winkler F; von Deimling A; Platten M; Wick W; Weiler M
    Oncotarget; 2015 Oct; 6(31):31050-68. PubMed ID: 25682871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.